BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 27543314)

  • 1. DNA repair mechanisms and their clinical impact in glioblastoma.
    Erasimus H; Gobin M; Niclou S; Van Dyck E
    Mutat Res Rev Mutat Res; 2016; 769():19-35. PubMed ID: 27543314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targets.
    Lozinski M; Bowden NA; Graves MC; Fay M; Tooney PA
    Cell Oncol (Dordr); 2021 Oct; 44(5):961-981. PubMed ID: 34057732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment considerations for MGMT-unmethylated glioblastoma.
    Taylor JW; Schiff D
    Curr Neurol Neurosci Rep; 2015 Jan; 15(1):507. PubMed ID: 25394859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The DNA damage/repair cascade in glioblastoma cell lines after chemotherapeutic agent treatment.
    Annovazzi L; Caldera V; Mellai M; Riganti C; Battaglia L; Chirio D; Melcarne A; Schiffer D
    Int J Oncol; 2015; 46(6):2299-308. PubMed ID: 25892134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.
    Messaoudi K; Clavreul A; Lagarce F
    Drug Discov Today; 2015 Jul; 20(7):899-905. PubMed ID: 25744176
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the DNA Damage Response to Overcome Cancer Drug Resistance in Glioblastoma.
    Ferri A; Stagni V; BarilĂ  D
    Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32664581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Updated Insights on EGFR Signaling Pathways in Glioma.
    Oprita A; Baloi SC; Staicu GA; Alexandru O; Tache DE; Danoiu S; Micu ES; Sevastre AS
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular targets in glioblastoma.
    Zorzan M; Giordan E; Redaelli M; Caretta A; Mucignat-Caretta C
    Future Oncol; 2015; 11(9):1407-20. PubMed ID: 25952786
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radiation-induced micro-RNA modulation in glioblastoma cells differing in DNA-repair pathways.
    Chaudhry MA; Sachdeva H; Omaruddin RA
    DNA Cell Biol; 2010 Sep; 29(9):553-61. PubMed ID: 20380575
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Broken beyond repair. Damaging DNA in glioblastoma cells with radiation and camptothecin.
    Darzynkiewicz Z
    Cancer Biol Ther; 2008 Mar; 7(3):374-5. PubMed ID: 18614857
    [No Abstract]   [Full Text] [Related]  

  • 12. The DNA methylome of glioblastoma multiforme.
    Martinez R; Esteller M
    Neurobiol Dis; 2010 Jul; 39(1):40-6. PubMed ID: 20064612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glioblastoma multiforme: Pathogenesis and treatment.
    Alifieris C; Trafalis DT
    Pharmacol Ther; 2015 Aug; 152():63-82. PubMed ID: 25944528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key concepts in glioblastoma therapy.
    Bartek J; Ng K; Bartek J; Fischer W; Carter B; Chen CC
    J Neurol Neurosurg Psychiatry; 2012 Jul; 83(7):753-60. PubMed ID: 22396442
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intratumoral heterogeneity identified at the epigenetic, genetic and transcriptional level in glioblastoma.
    Parker NR; Hudson AL; Khong P; Parkinson JF; Dwight T; Ikin RJ; Zhu Y; Cheng ZJ; Vafaee F; Chen J; Wheeler HR; Howell VM
    Sci Rep; 2016 Mar; 6():22477. PubMed ID: 26940435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association between response to primary treatments and MGMT status in glioblastoma.
    Franceschi E; Tosoni A; Pozzati E; Brandes AA
    Expert Rev Anticancer Ther; 2008 Nov; 8(11):1781-6. PubMed ID: 18983238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms of temozolomide resistance in glioblastoma multiforme.
    Johannessen TC; Bjerkvig R
    Expert Rev Anticancer Ther; 2012 May; 12(5):635-42. PubMed ID: 22594898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GBM radiosensitizers: dead in the water…or just the beginning?
    Bindra RS; Chalmers AJ; Evans S; Dewhirst M
    J Neurooncol; 2017 Sep; 134(3):513-521. PubMed ID: 28762004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in epigenetic glioblastoma therapy.
    Lee DH; Ryu HW; Won HR; Kwon SH
    Oncotarget; 2017 Mar; 8(11):18577-18589. PubMed ID: 28099914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual mTORC1/2 blockade inhibits glioblastoma brain tumor initiating cells in vitro and in vivo and synergizes with temozolomide to increase orthotopic xenograft survival.
    Luchman HA; Stechishin OD; Nguyen SA; Lun XQ; Cairncross JG; Weiss S
    Clin Cancer Res; 2014 Nov; 20(22):5756-67. PubMed ID: 25316808
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.